Pulmonary embolism-Pipeline Insight, 2021 | Analytical Research Cognizance

Pulmonary embolism-Pipeline Insight, 2021

Published by ARCDI001
Report ID 1667936
Published date Mar 30, 2021
Category Pharmaceuticals and Healthcare
Total Pages 60
Choose license type Buy Now
Request a Sample Enquiry Before Buying Check Discount

DelveInsight’s, “Pulmonary embolism - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Pulmonary embolism Understanding
Pulmonary embolism: Overview
A pulmonary embolism is a blockage in the pulmonary artery, which supplies the blood to the lungs. Although pulmonary embolism can arise from anywhere in the body, most commonly it arises from the calf veins. It usually happens when a blood clot breaks loose and travels through the bloodstream to the lungs. Symptoms of a pulmonary embolism include sudden shortness of breath, pain in and around the chest and coughing. Pulmonary embolism is commonly detected through the following tests: Computed tomography (CT) scan, Lung scan, Blood tests (including the D-dimer test), Pulmonary angiogram, Ultrasound of the leg, Magnetic resonance imaging (MRI) of the legs or lungs. Medicines like anticoagulants, or blood thinners, keep blood clots from getting larger and stop new clots from forming; thrombolytics are medicines used to dissolve blood clots. A vena cava filter may be used in some people who cannot take blood thinners. Catheter-assisted thrombus removal procedure uses a flexible tube to reach a blood clot in your lung and a tool is inserted in the tube to break up the clot or to deliver medicine through the tube.
"Pulmonary embolism - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary embolism pipeline landscape is provided which includes the disease overview and Pulmonary embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary embolism.

Pulmonary embolism Emerging Drugs Chapters
This segment of the Pulmonary embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary embolism Emerging Drugs
Recombinant staphylokinase: Supergene
Recombinant staphylokinase contains Forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.

Reteplase: Angde Biotech Pharmaceutical
Reteplase is a recombinant human tissue-type plasminogen activator derivative. It is a non-glycosylated deletion mutein of tissue plasminogen activator (tPA), containing the kringle 2 and the protease domains of human tPA. The drug is in Phase II clinical developmental studies for the treatment of acute pulmonary embolism.
Further product details are provided in the report……..

Pulmonary embolism: Therapeutic Assessment
This segment of the report provides insights about the different Pulmonary embolism drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Pulmonary embolism
There are approx. 5+ key companies which are developing the therapies for Pulmonary embolism. The companies which have their Pulmonary embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Pulmonary embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary embolism: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary embolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary embolism drugs.

Pulmonary embolism Report Insights
Pulmonary embolism Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Pulmonary embolism Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Pulmonary embolism drugs?
How many Pulmonary embolism drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary embolism?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary embolism therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Pulmonary embolism and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Supergene
Organicell Regenerative Medicine
Angde Biotech Pharmaceutical
Yuhan

Key Products
Recombinant staphylokinase
Zofin
Reteplase
YHP 1906

Introduction
Executive Summary
Pulmonary embolism: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pulmonary embolism – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Pulmonary embolism companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Pulmonary embolism Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Recombinant staphylokinase: Supergene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Reteplase: Angde Biotech Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Zofin: Organicell Regenerative Medicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Pulmonary embolism Key Companies
Pulmonary embolism Key Products
Pulmonary embolism- Unmet Needs
Pulmonary embolism- Market Drivers and Barriers
Pulmonary embolism- Future Perspectives and Conclusion
Pulmonary embolism Analyst Views
Pulmonary embolism Key Companies
Appendix

Table 1 Total Products for Pulmonary embolism
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Pulmonary embolism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products